InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC.
| Revenue (Most Recent Fiscal Year) | $4.60M |
| Net Income (Most Recent Fiscal Year) | $-7.68M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.60 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.42 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -168.71% |
| Net Margin (Trailing 12 Months) | -168.87% |
| Return on Equity (Trailing 12 Months) | -107.93% |
| Return on Assets (Trailing 12 Months) | -82.97% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.49 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.04 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.06 |
| Inventory Turnover (Trailing 12 Months) | 3.04 |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.82 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-12.09 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 1.21M |
| Free Float | 1.19M |
| Market Capitalization | $2.96M |
| Average Volume (Last 20 Days) | 0.21M |
| Beta (Past 60 Months) | 0.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.43% |
| Percentage Held By Institutions (Latest 13F Reports) | 20.12% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |